Recent scientific advances have identified blood-based biomarkers capable of detecting tau protein accumulation, potentially enabling earlier identification of individuals at heightened risk for Alzheimer's disease. While these diagnostic tools show promising results in predicting dementia progression, researchers emphasize that standardization, clinical validation, and implementation guidelines remain critical before widespread adoption in medical practice.

Summary auto-generated by AI from the original publisher's content. Editorial standards.